​New immunity project for malaria and HIV vaccines receives funding

Stuart Lab awarded U19 funding from NIH to study immunity against malaria and HIV infection in partnership with Fred Hutchinson Cancer Research Center

October 2017 ― Dr. Ken Stuart, founder of CID Research, and his colleagues won funding for a five-year program as part of the Human Immunology Project Consortium (HIPC) totaling $13.3 million to advance our understanding of immune responses to malaria and HIV-1 infection and to develop vaccines against these diseases.

The new program has two projects, which will identify detailed immune responses that correlate with vaccine protection against Plasmodium falciparum malaria and HIV-1. The program is a partnership between CID Research and the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center. Involved faculty from CID Research include Ken Stuart, Principal Investigator and the Malaria Project Lead; and Dr. John Aitchison, President and Director of CID Research, and Systems Biology Core Lead. Fred Hutchinson faculty include: Dr. Julie McElrath, HIV-1 Project Lead and Clinical Core Lead; and Dr. Raphael Gottardo, Data Core Lead.

The HIPC program was established in 2010, and renewed in 2015, by the National Institute of Allergy and Infectious Diseases (NIAID) Division of Allergy, Immunology, and Transplantation as part of the overall NIAID focus on human immunology.

Malaria and HIV/AIDS are two of the most devastating infectious diseases, impacting millions of people worldwide. Effective vaccines against the pathogens that cause these diseases, HIV-1 and P. falciparum, have proven elusive; and traditional vaccine approaches are unlikely to succeed in eradicating either disease.

In addition to our limited understanding of the desired immune responses to confer protection against the pathogens and our limited ability to elicit such responses, vaccine efficacy is also confounded by the diversity of pathogens, human populations, environmental exposures, and health status.

This program’s strategies for analyzing the range of immune responses to infection and vaccination hold promise for garnering fundamental insights into the complexity of the human immune system as a whole. Such insights have the potential for furthering vaccine development and for treating immune-related diseases more broadly.


The Center for Infectious Disease Research is the largest independent, non-profit organization in the U.S. focused solely on infectious disease research. Our research is the foundation for new drugs, vaccines and diagnostics that benefit those who need our help most: the fourteen million who will otherwise die each year from infectious diseases, including malaria, HIV/AIDS and tuberculosis. Founded in 1976, CID Research partners with key collaborators around the globe and strives to make discoveries that will save lives. For more information, visit www.cidresearch.org.


206.256.7252, communications@cidresearch.org

See more CID Research News & Press